Pain! Wann gehts wieder nach Norden? (Seite 4)

Beitrag schreiben

Begriffe und/oder Benutzer


Antwort auf Beitrag Nr.: 62.509.154 von clearasil am 28.01.20 15:00:02…

Cassava’s Drug Discovery

"SAVA has two products in its pipeline for which it owns proprietary, worldwide rights, without royalty or milestone obligations.

PTI-125 is an oral, small molecule drug that is now in the middle of a Phase 2(B) study, with results expected by mid-2020. It receives long-term scientific & financial support from the National Institute of Health (NIH)
PTI-125Dx is an Alzheimer’s detection (diagnostic) system. It is currently undergoing clinical testing.

Both products will enter the pivotal (or clinical) trial phase in 2021, and after positive results will be ready to be marketed.

Currently, Alzheimer’s can be definitively diagnosed only after death. Therefore, if the PT-125Dx’s clinical tests are successful, along with a successful PT-125, this will imply bumper prospects for the company.

For SAVA, its current results do not matter. What matters is the success of their trials. The progress of whatever is happening is known only to the insiders."

"Between 26 Sep 2019 and 31 Dec 2019, SAVA insiders bought over 700,000 shares between $1.02 and $5.53.

The last purchase was by Barbier Remi (CEO) at $5.53. The largest purchase of 423,000 shares was made by a director at $2.20."
Cassava Sciences | 6,480 €…

Key results published from the Phase 2a study include:

Total tau (T-tau) decreased 20% (p<0.001)
Phosphorylated tau (P-tau) decreased 34% (p<0.0001)
Neurofilament light chain (NfL), a marker for neurodegeneration, decreased 22% (p<0.0001)
Neurogranin, a marker for cognitive decline, decreased 32% (p<0.0001)
Neuroinflammatory marker YKL-40, an indicator of microglial activation, decreased 9% (p<0.0001)
Proinflammatory Interleukin 6 (IL-6) decreased 14% (p<0.0001)
Proinflammatory Interleukin 1 beta (IL-1β) decreased 11% (p<0.0001)
Proinflammatory Tumor Necrosis Factor alpha (TNFα) decreased 5% (p<0.001)
The ratio of CSF P-tau to Aβ42, a widely accepted biochemical value of Alzheimer’s disease, improved in all patients (p<0.001)

"Nadav Friedmann, MD, PhD, Chief Medical Officer at Cassava Sciences commented, “We are pleased to share these study results in JPAD. This publication provides clinical insights into how our lead drug candidate, PTI-125, could make an important difference for patients living with Alzheimer’s disease. In this study, PTI-125 reduced multiple biomarkers of Alzheimer’s disease, including neurodegeneration and neuroinflammation. To our knowledge, no other drug has shown such effects in Alzheimer’s patients.”

Published results from this study demonstrate that biomarkers of Alzheimer’s disease pathology (P-tau, total tau and Aβ42), neurodegeneration (NfL and neurogranin) and neuroinflammation (YKL-40, IL-6, IL-1β and TNFα) improved significantly after 28 days of treatment with PTI-125. Biomarker reductions were at least p< 0.001 by paired t-test. Biomarkers effects were seen in all patients in both cerebrospinal fluid (CSF) and plasma. PTI-125 was safe and well tolerated, with no observable drug-related adverse events.

Lindsay H. Burns, PhD, VP Neuroscience at Cassava Sciences, added, “This publication supports PTI-125 as a new and potentially disease-modifying drug treatment for Alzheimer’s disease. Significant improvements observed across multiple biomarkers imply a slower rate of neurodegeneration or a suppression of disease processes. These treatment effects are consistent with the drug’s mechanism of action and over ten years of basic research and preclinical data.”
Cassava Sciences | 7,220 €
Antwort auf Beitrag Nr.: 62.645.878 von clearasil am 11.02.20 14:52:29Heute -80%.
Cassava Sciences | 1,460 €

Beitrag zu dieser Diskussion schreiben